JP2012515213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515213A5 JP2012515213A5 JP2011546329A JP2011546329A JP2012515213A5 JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5 JP 2011546329 A JP2011546329 A JP 2011546329A JP 2011546329 A JP2011546329 A JP 2011546329A JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- individual
- combination
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14453709P | 2009-01-14 | 2009-01-14 | |
| US61/144,537 | 2009-01-14 | ||
| US29309610P | 2010-01-07 | 2010-01-07 | |
| US61/293,096 | 2010-01-07 | ||
| PCT/US2010/021029 WO2010083298A1 (en) | 2009-01-14 | 2010-01-14 | Methods and compositions containing mtor inhibitors for enhancing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515213A JP2012515213A (ja) | 2012-07-05 |
| JP2012515213A5 true JP2012515213A5 (enExample) | 2012-12-27 |
Family
ID=42340082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546329A Pending JP2012515213A (ja) | 2009-01-14 | 2010-01-14 | 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100196311A1 (enExample) |
| EP (1) | EP2375897A4 (enExample) |
| JP (1) | JP2012515213A (enExample) |
| CN (1) | CN102281761A (enExample) |
| CA (1) | CA2748931A1 (enExample) |
| WO (1) | WO2010083298A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
| US11213583B2 (en) | 2014-02-05 | 2022-01-04 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| CA2990705A1 (en) * | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| EP3324983A4 (en) * | 2015-07-20 | 2019-04-10 | Mayo Foundation for Medical Education and Research | METHOD AND MATERIALS FOR PRODUCING T-CELLS |
| JP7653759B2 (ja) * | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN117731763A (zh) * | 2016-06-24 | 2024-03-22 | 麦克马斯特大学 | 过继细胞转移与溶瘤病毒组合疗法 |
| JP2020500930A (ja) | 2016-11-23 | 2020-01-16 | ノバルティス アーゲー | エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法 |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1061949B1 (en) * | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| WO2005003335A2 (en) * | 2003-06-12 | 2005-01-13 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rapamycin resistant t cells and therapeutic uses thereof |
| WO2003038062A2 (en) * | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| US20060094674A1 (en) * | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| EP1408106B1 (en) * | 2002-10-11 | 2007-02-14 | Sentoclone Therapeutics AB | Cancer immuno-therapy |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2008042814A2 (en) * | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| US8765462B2 (en) * | 2007-05-04 | 2014-07-01 | University Health Network | IL-12 immunotherapy for cancer |
| AU2009279661A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
-
2010
- 2010-01-14 EP EP10732083.0A patent/EP2375897A4/en not_active Withdrawn
- 2010-01-14 JP JP2011546329A patent/JP2012515213A/ja active Pending
- 2010-01-14 CN CN2010800048759A patent/CN102281761A/zh active Pending
- 2010-01-14 WO PCT/US2010/021029 patent/WO2010083298A1/en not_active Ceased
- 2010-01-14 CA CA2748931A patent/CA2748931A1/en not_active Abandoned
- 2010-01-14 US US12/687,650 patent/US20100196311A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment | |
| Dzutsev et al. | Microbes and cancer | |
| Liu et al. | Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond | |
| Wang et al. | Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy | |
| Chen et al. | Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients | |
| Song et al. | Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages | |
| JP2015134813A5 (enExample) | ||
| Hu et al. | Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice | |
| Zou et al. | Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer | |
| JP2019512020A5 (enExample) | ||
| Chandwaskar et al. | Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease | |
| US20200323905A1 (en) | Methods and compositions for modulating the immune system | |
| JP2010508834A5 (enExample) | ||
| Viudez-Pareja et al. | Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment | |
| Yue et al. | Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: insights, therapies and future directions | |
| Pai et al. | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels | |
| Gras et al. | The inhibition of Th17 immune response in vitro and in vivo by the carbosilane dendrimer 2G-NN16 | |
| Madan et al. | Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells | |
| Nobel et al. | STAT signaling in the intestine | |
| Xiong et al. | Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor | |
| Callejas et al. | Interleukin-4 programmed macrophages suppress colitis and do not enhance infectious-colitis, inflammation-associated colon cancer or airway hypersensitivity | |
| US20160067272A1 (en) | Methods for treating immune diseases | |
| Wang et al. | Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor | |
| Zhang et al. | IL-35 inhibits acute graft-versus-host disease in a mouse model | |
| Huart et al. | Could protons and carbon ions be the silver bullets against pancreatic cancer? |